Live Link
Real-time data linking capability for continuous patient journey tracking
Company profile
Company profile
Truveta is a healthcare data and analytics company built with and owned by leading US health systems to improve patient care and accelerate medical research. The company provides the most complete, real-time view of US healthcare through Truveta Data, covering over 130 million patients with longitudinally linked EHR data, closed claims, devices, images, social determinants of health (SDOH), mother-child records, multiomics, and mortality data that is updated daily. Truveta serves pharmaceutical companies, medical device manufacturers, public health organizations, healthcare providers, and academic researchers across the entire product lifecycle—from R&D and clinical trial optimization to post-market safety surveillance and health economics outcomes research (HEOR). The platform combines three core offerings: Truveta Data for comprehensive patient journey data, Truveta Intelligence for rapid analytics that deliver answers in minutes rather than months, and Truveta Evidence for rigorous, audit-ready research studies supported by expert services. Truveta's proprietary Truveta Language Model processes clinical notes and unstructured data at scale, while the platform's regulatory-grade data quality and full traceability support submissions to FDA, CMS, and global regulatory agencies. With over 350 publications, 250 conference presentations, and 100+ regulatory projects, Truveta has established itself as a trusted partner for generating real-world evidence. The company's data encompasses 45 million devices, 10+ years of longitudinal patient histories, and is representative of diverse patient populations across multiple care settings and geographies, enabling research into health equity, treatment effectiveness, safety signals, and healthcare optimization.
Company description Truveta official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas · Embedded deployment with recorded integration context.
Company milestones
Real-world studies on adalimumab biosimilar switching (1 in 7 patients returned to Humira), progesterone-containing HRT prescribing trends (488% increase 2018-2026), GLP-1 RA discontinuation patterns, device safety and effectiveness studies across cardiovascular and other therapeutic areas
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Real-time data linking capability for continuous patient journey tracking
A complete, living view of patient care with 130M+ patients updated daily
Build trust through rigorous analytics and expertise with audit-ready evidence
Design rigorous studies alongside experts and deliver transparent, audit-ready evidence
Answers in minutes, not months with AI-powered healthcare analytics
AI model for processing clinical notes and unstructured healthcare data
Explore every disease with longitudinal, clinical context for oncology
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Human vaccines & immunotherapeutics · Dec 1, 2026
From fragmented records to living evidence: health system-governed, artificial intelligence-driven, continuously updated real-world clinical data from Truveta.JAMIA open · Aug 1, 2026
Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.BMJ open · Jul 21, 2026
Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025).Journal of managed care & specialty pharmacy · Jul 1, 2026
Heart Failure Trajectories After Guideline-Directed Medical Therapy.JAMA network open · May 1, 2026
Evaluating changes in lidocaine and opioid administration on the day of IUD insertion, 2018-2025.Contraception · Apr 1, 2026
Clinical validation
No linked records are currently available.
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
covered in Truveta Data
from closed claims data
tracked with device-level granularity
longitudinal patient data
real-time data refresh
research output
across US and global agencies
Comparing real-world outcomes for medical device to demonstrate lower bleeding risk vs. competitor device
Evidence of lower bleeding risk vs. competitor device built confidence and accelerated adoption
Supporting expanded use by demonstrating slower kidney disease progression
Linked outcomes showed slower kidney disease progression, strengthening value story for coverage
Assessing impact of device design on safety through comparative infection risk analysis
Comparative infection risk analysis informed product design and safety monitoring
De-risking clinical trial design by refining eligibility criteria and confirming trial feasibility
Dataset 3x larger than legacy registry used to refine eligibility criteria and confirm trial feasibility
05 · Leadership
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Recent articles published on Truveta's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies providing AI-powered analytics for population health management, healthcare data integration and analysis, risk stratification, care gap identification, or value-based care analytics. Focuses on analyzing data across patient populations to improve outcomes at scale and enable data-driven decision-making across health systems.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.